

Global Immuno-oncology Drugs Market Research Report 2025(Status and Outlook)

<https://marketpublishers.com/r/G1A6CE4CF3D0EN.html>

Date: March 2025

Pages: 261

Price: US\$ 3,680.00 (Single User License)

ID: G1A6CE4CF3D0EN

Abstracts

Report Overview

Immunotherapy is treatment that uses a certain part of a person's immune system to fight diseases which is done by stimulating one's own immune system to work harder to attack cancer cells or by giving immune system components, such as man-made immune system proteins. Immunotherapy includes treatments that work in different ways. Some boost the body's immune system in a very general way and others help train the immune system to attack cancer cells specifically.

This report provides a deep insight into the global Immuno-oncology Drugs market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.

The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Immuno-oncology Drugs Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.

In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Immuno-oncology Drugs market in any manner.

Global Immuno-oncology Drugs Market: Market Segmentation Analysis

The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.

Key Company

Amgen

Inc

AstraZeneca

Plc

Bristol-Myers Squibb

Celgene Corporation

Eli Lilly and Company

Merck & Co.

Hoffmann-La Roche AG

Johnson & Johnson

Novartis International AG

AbbVie

Inc.

Pfizer Inc.

Sanofi S.A.

EMD Serono

Inc.

Gilead Sciences Inc.

Prometheus Therapeutics & Diagnostics

Aduro BioTech

Galena Biopharma

Bavarian Nordic

Celldex Therapeutics

ImmunoCellular Therapeutics

Incyte

Dendreon Corporation

Agilent Technologies Inc.

Agenus Inc.

Enzo Biochem

Inc.

Market Segmentation (by Type)

Immune Checkpoint Inhibitors

Immune System Modulators

Cancer Vaccines

Oncolytic Virus

Others

Market Segmentation (by Application)

Hospitals

Clinics

Ambulatory Surgical Centers

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Immuno-oncology Drugs Market

Overview of the regional outlook of the Immuno-oncology Drugs Market:

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value (USD Billion) data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Immuno-oncology Drugs Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.

Chapter 12 is the main points and conclusions of the report.

Contents

Table of Contents

1 Research Methodology and Statistical Scope

1.1 Market Definition and Statistical Scope of Immuno-oncology Drugs

1.2 Key Market Segments

1.2.1 Immuno-oncology Drugs Segment by Type

1.2.2 Immuno-oncology Drugs Segment by Application

1.3 Methodology & Sources of Information

1.3.1 Research Methodology

1.3.2 Research Process

1.3.3 Market Breakdown and Data Triangulation

1.3.4 Base Year

1.3.5 Report Assumptions & Caveats

2 Global Immuno-oncology Drugs Market Overview

2.1 Global Market Overview

2.1.1 Global Immuno-oncology Drugs Market Size (M USD) Estimates and Forecasts (2020-2033)

2.1.2 Global Immuno-oncology Drugs Sales Estimates and Forecasts (2020-2033)

2.2 Market Segment Executive Summary

2.3 Global Market Size by Region

3 Global Immuno-oncology Drugs Market Competitive Landscape

3.1 Company Assessment Quadrant

3.2 Global Immuno-oncology Drugs Product Life Cycle

3.3 Global Immuno-oncology Drugs Sales by Manufacturers (2020-2025)

3.4 Global Immuno-oncology Drugs Revenue Market Share by Manufacturers (2020-2025)

3.5 Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Immuno-oncology Drugs Average Price by Manufacturers (2020-2025)

3.7 Manufacturers Immuno-oncology Drugs Manufacturing Sites, Area Served, Product Type

3.8 Immuno-oncology Drugs Market Competitive Situation and Trends

3.8.1 Immuno-oncology Drugs Market Concentration Rate

3.8.2 Global 5 and 10 Largest Immuno-oncology Drugs Players Market Share by Revenue

3.8.3 Mergers & Acquisitions, Expansion

4 Immuno-oncology Drugs Industry Chain Analysis

4.1 Immuno-oncology Drugs Industry Chain Analysis

4.2 Market Overview of Key Raw Materials

- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis
- 5 The Development and Dynamics of Immuno-oncology Drugs Market
 - 5.1 Key Development Trends
 - 5.2 Driving Factors
 - 5.3 Market Challenges
 - 5.4 Industry News
 - 5.4.1 New Product Developments
 - 5.4.2 Mergers & Acquisitions
 - 5.4.3 Expansions
 - 5.4.4 Collaboration/Supply Contracts
 - 5.5 PEST Analysis
 - 5.5.1 Industry Policies Analysis
 - 5.5.2 Economic Environment Analysis
 - 5.5.3 Social Environment Analysis
 - 5.5.4 Technological Environment Analysis
 - 5.6 Global Immuno-oncology Drugs Market Porter's Five Forces Analysis
 - 5.6.1 Global Trade Frictions
 - 5.6.2 Global Trade Frictions and Their Impacts to Immuno-oncology Drugs Market
 - 5.7 ESG Ratings of Leading Companies
- 6 Global Immuno-oncology Drugs Market by Region
 - 6.1 Global Immuno-oncology Drugs Market Size by Region
 - 6.1.1 Global Immuno-oncology Drugs Market Size by Region
 - 6.1.2 Global Immuno-oncology Drugs Market Size Market Share by Region
 - 6.2 Global Immuno-oncology Drugs Sales by Region
 - 6.2.1 Global Immuno-oncology Drugs Sales by Region
 - 6.2.2 Global Immuno-oncology Drugs Sales Market Share by Region
- 7 North America Market Overview
 - 7.1 North America Immuno-oncology Drugs Market Size by Country
 - 7.1.1 USA Market Overview
 - 7.1.2 Canada Market Overview
 - 7.1.3 Mexico Market Overview
 - 7.2 North America Immuno-oncology Drugs Market Size by Type
 - 7.3 North America Immuno-oncology Drugs Market Size by Application
- 8 Europe Market Overview
 - 8.1 Europe Immuno-oncology Drugs Market Size by Country
 - 8.1.1 Germany Market Overview
 - 8.1.2 France Market Overview
 - 8.1.3 U.K. Market Overview

- 8.1.4 Italy Market Overview
- 8.1.5 Spain Market Overview
- 8.2 Europe Immuno-oncology Drugs Market Size by Type
- 8.3 Europe Immuno-oncology Drugs Market Size by Application
- 9 Asia-Pacific Market Overview
 - 9.1 Asia-Pacific Immuno-oncology Drugs Market Size by Country
 - 9.1.1 China Market Overview
 - 9.1.2 Japan Market Overview
 - 9.1.3 South Korea Market Overview
 - 9.1.4 India Market Overview
 - 9.1.5 Southeast Asia Market Overview
 - 9.2 Asia-Pacific Immuno-oncology Drugs Market Size by Type
 - 9.3 Asia-Pacific Immuno-oncology Drugs Market Size by Application
- 10 South America Market Overview
 - 10.1 South America Immuno-oncology Drugs Market Size by Country
 - 10.1.1 Brazil Market Overview
 - 10.1.2 Argentina Market Overview
 - 10.1.3 Columbia Market Overview
 - 10.2 South America Immuno-oncology Drugs Market Size by Type
 - 10.3 South America Immuno-oncology Drugs Market Size by Application
- 11 Middle East and Africa Market Overview
 - 11.1 Middle East and Africa Immuno-oncology Drugs Market Size by Country
 - 11.1.1 Saudi Arabia Market Overview
 - 11.1.2 UAE Market Overview
 - 11.1.3 Egypt Market Overview
 - 11.1.4 Nigeria Market Overview
 - 11.1.5 South Africa Market Overview
 - 11.2 Middle East and Africa Immuno-oncology Drugs Market Size by Type
 - 11.3 Middle East and Africa Immuno-oncology Drugs Market Size by Application
- 12 Immuno-oncology Drugs Market Production by Region
 - 12.1 Global Production of Immuno-oncology Drugs by Region(2020-2025)
 - 12.2 Global Immuno-oncology Drugs Revenue Market Share by Region (2020-2025)
 - 12.3 Global Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2020-2025)
 - 12.4 North America Immuno-oncology Drugs Production
 - 12.4.1 North America Immuno-oncology Drugs Production Growth Rate (2020-2025)
 - 12.4.2 North America Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2020-2025)
 - 12.5 Europe Immuno-oncology Drugs Production

- 12.5.1 Europe Immuno-oncology Drugs Production Growth Rate (2020-2025)
- 12.5.2 Europe Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 12.6 Japan Immuno-oncology Drugs Production (2020-2025)
 - 12.6.1 Japan Immuno-oncology Drugs Production Growth Rate (2020-2025)
 - 12.6.2 Japan Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 12.7 China Immuno-oncology Drugs Production (2020-2025)
 - 12.7.1 China Immuno-oncology Drugs Production Growth Rate (2020-2025)
 - 12.7.2 China Immuno-oncology Drugs Production, Revenue, Price and Gross Margin (2020-2025)
- 13 Immuno-oncology Drugs Market Segmentation by Type
 - 13.1 Evaluation Matrix of Segment Market Development Potential (Type)
 - 13.2 Global Immuno-oncology Drugs Sales Market Share by Type (2020-2033)
 - 13.3 Global Immuno-oncology Drugs Market Size Market Share by Type (2020-2033)
 - 13.4 Global Immuno-oncology Drugs Price by Type (2020-2033)
- 14 Immuno-oncology Drugs Market Segmentation by Application
 - 14.1 Evaluation Matrix of Segment Market Development Potential (Application)
 - 14.2 Global Immuno-oncology Drugs Market Sales by Application (2020-2033)
 - 14.3 Global Immuno-oncology Drugs Market Size (M USD) by Application (2020-2033)
 - 14.4 Global Immuno-oncology Drugs Sales Growth Rate by Application (2020-2033)
- 15 Key Companies Profile
 - 15.1 Amgen
 - 15.1.1 Amgen Basic Information
 - 15.1.2 Amgen Immuno-oncology Drugs Product Overview
 - 15.1.3 Amgen Immuno-oncology Drugs Product Market Performance
 - 15.1.4 Amgen Business Overview
 - 15.1.5 Amgen SWOT Analysis
 - 15.1.6 Amgen Recent Developments
 - 15.2 Inc
 - 15.2.1 Inc Basic Information
 - 15.2.2 Inc Immuno-oncology Drugs Product Overview
 - 15.2.3 Inc Immuno-oncology Drugs Product Market Performance
 - 15.2.4 Inc Business Overview
 - 15.2.5 Inc SWOT Analysis
 - 15.2.6 Inc Recent Developments
 - 15.3 AstraZeneca
 - 15.3.1 AstraZeneca Basic Information
 - 15.3.2 AstraZeneca Immuno-oncology Drugs Product Overview

- 15.3.3 AstraZeneca Immuno-oncology Drugs Product Market Performance
- 15.3.4 AstraZeneca Business Overview
- 15.3.5 AstraZeneca SWOT Analysis
- 15.3.6 AstraZeneca Recent Developments
- 15.4 Plc
 - 15.4.1 Plc Basic Information
 - 15.4.2 Plc Immuno-oncology Drugs Product Overview
 - 15.4.3 Plc Immuno-oncology Drugs Product Market Performance
 - 15.4.4 Plc Business Overview
 - 15.4.5 Plc Recent Developments
- 15.5 Bristol-Myers Squibb
 - 15.5.1 Bristol-Myers Squibb Basic Information
 - 15.5.2 Bristol-Myers Squibb Immuno-oncology Drugs Product Overview
 - 15.5.3 Bristol-Myers Squibb Immuno-oncology Drugs Product Market Performance
 - 15.5.4 Bristol-Myers Squibb Business Overview
 - 15.5.5 Bristol-Myers Squibb Recent Developments
- 15.6 Celgene Corporation
 - 15.6.1 Celgene Corporation Basic Information
 - 15.6.2 Celgene Corporation Immuno-oncology Drugs Product Overview
 - 15.6.3 Celgene Corporation Immuno-oncology Drugs Product Market Performance
 - 15.6.4 Celgene Corporation Business Overview
 - 15.6.5 Celgene Corporation Recent Developments
- 15.7 Eli Lilly and Company
 - 15.7.1 Eli Lilly and Company Basic Information
 - 15.7.2 Eli Lilly and Company Immuno-oncology Drugs Product Overview
 - 15.7.3 Eli Lilly and Company Immuno-oncology Drugs Product Market Performance
 - 15.7.4 Eli Lilly and Company Business Overview
 - 15.7.5 Eli Lilly and Company Recent Developments
- 15.8 Merck and Co.
 - 15.8.1 Merck and Co. Basic Information
 - 15.8.2 Merck and Co. Immuno-oncology Drugs Product Overview
 - 15.8.3 Merck and Co. Immuno-oncology Drugs Product Market Performance
 - 15.8.4 Merck and Co. Business Overview
 - 15.8.5 Merck and Co. Recent Developments
- 15.9 Hoffmann-La Roche AG
 - 15.9.1 Hoffmann-La Roche AG Basic Information
 - 15.9.2 Hoffmann-La Roche AG Immuno-oncology Drugs Product Overview
 - 15.9.3 Hoffmann-La Roche AG Immuno-oncology Drugs Product Market Performance
 - 15.9.4 Hoffmann-La Roche AG Business Overview

- 15.9.5 Hoffmann-La Roche AG Recent Developments
- 15.10 Johnson and Johnson
 - 15.10.1 Johnson and Johnson Basic Information
 - 15.10.2 Johnson and Johnson Immuno-oncology Drugs Product Overview
 - 15.10.3 Johnson and Johnson Immuno-oncology Drugs Product Market Performance
 - 15.10.4 Johnson and Johnson Business Overview
 - 15.10.5 Johnson and Johnson Recent Developments
- 15.11 Novartis International AG
 - 15.11.1 Novartis International AG Basic Information
 - 15.11.2 Novartis International AG Immuno-oncology Drugs Product Overview
 - 15.11.3 Novartis International AG Immuno-oncology Drugs Product Market Performance
 - 15.11.4 Novartis International AG Business Overview
 - 15.11.5 Novartis International AG Recent Developments
- 15.12 AbbVie
 - 15.12.1 AbbVie Basic Information
 - 15.12.2 AbbVie Immuno-oncology Drugs Product Overview
 - 15.12.3 AbbVie Immuno-oncology Drugs Product Market Performance
 - 15.12.4 AbbVie Business Overview
 - 15.12.5 AbbVie Recent Developments
- 15.13 Inc.
 - 15.13.1 Inc. Basic Information
 - 15.13.2 Inc. Immuno-oncology Drugs Product Overview
 - 15.13.3 Inc. Immuno-oncology Drugs Product Market Performance
 - 15.13.4 Inc. Business Overview
 - 15.13.5 Inc. Recent Developments
- 15.14 Pfizer Inc.
 - 15.14.1 Pfizer Inc. Basic Information
 - 15.14.2 Pfizer Inc. Immuno-oncology Drugs Product Overview
 - 15.14.3 Pfizer Inc. Immuno-oncology Drugs Product Market Performance
 - 15.14.4 Pfizer Inc. Business Overview
 - 15.14.5 Pfizer Inc. Recent Developments
- 15.15 Sanofi S.A.
 - 15.15.1 Sanofi S.A. Basic Information
 - 15.15.2 Sanofi S.A. Immuno-oncology Drugs Product Overview
 - 15.15.3 Sanofi S.A. Immuno-oncology Drugs Product Market Performance
 - 15.15.4 Sanofi S.A. Business Overview
 - 15.15.5 Sanofi S.A. Recent Developments
- 15.16 EMD Serono

- 15.16.1 EMD Serono Basic Information
- 15.16.2 EMD Serono Immuno-oncology Drugs Product Overview
- 15.16.3 EMD Serono Immuno-oncology Drugs Product Market Performance
- 15.16.4 EMD Serono Business Overview
- 15.16.5 EMD Serono Recent Developments
- 15.17 Inc.
- 15.17.1 Inc. Basic Information
- 15.17.2 Inc. Immuno-oncology Drugs Product Overview
- 15.17.3 Inc. Immuno-oncology Drugs Product Market Performance
- 15.17.4 Inc. Business Overview
- 15.17.5 Inc. Recent Developments
- 15.18 Gilead Sciences Inc.
- 15.18.1 Gilead Sciences Inc. Basic Information
- 15.18.2 Gilead Sciences Inc. Immuno-oncology Drugs Product Overview
- 15.18.3 Gilead Sciences Inc. Immuno-oncology Drugs Product Market Performance
- 15.18.4 Gilead Sciences Inc. Business Overview
- 15.18.5 Gilead Sciences Inc. Recent Developments
- 15.19 Prometheus Therapeutics and Diagnostics
- 15.19.1 Prometheus Therapeutics and Diagnostics Basic Information
- 15.19.2 Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Product Overview
- 15.19.3 Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Product Market Performance
- 15.19.4 Prometheus Therapeutics and Diagnostics Business Overview
- 15.19.5 Prometheus Therapeutics and Diagnostics Recent Developments
- 15.20 Aduro BioTech
- 15.20.1 Aduro BioTech Basic Information
- 15.20.2 Aduro BioTech Immuno-oncology Drugs Product Overview
- 15.20.3 Aduro BioTech Immuno-oncology Drugs Product Market Performance
- 15.20.4 Aduro BioTech Business Overview
- 15.20.5 Aduro BioTech Recent Developments
- 15.21 Galena Biopharma
- 15.21.1 Galena Biopharma Basic Information
- 15.21.2 Galena Biopharma Immuno-oncology Drugs Product Overview
- 15.21.3 Galena Biopharma Immuno-oncology Drugs Product Market Performance
- 15.21.4 Galena Biopharma Business Overview
- 15.21.5 Galena Biopharma Recent Developments
- 15.22 Bavarian Nordic
- 15.22.1 Bavarian Nordic Basic Information

- 15.22.2 Bavarian Nordic Immuno-oncology Drugs Product Overview
- 15.22.3 Bavarian Nordic Immuno-oncology Drugs Product Market Performance
- 15.22.4 Bavarian Nordic Business Overview
- 15.22.5 Bavarian Nordic Recent Developments
- 15.23 Celldex Therapeutics
 - 15.23.1 Celldex Therapeutics Basic Information
 - 15.23.2 Celldex Therapeutics Immuno-oncology Drugs Product Overview
 - 15.23.3 Celldex Therapeutics Immuno-oncology Drugs Product Market Performance
 - 15.23.4 Celldex Therapeutics Business Overview
 - 15.23.5 Celldex Therapeutics Recent Developments
- 15.24 ImmunoCellular Therapeutics
 - 15.24.1 ImmunoCellular Therapeutics Basic Information
 - 15.24.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Overview
 - 15.24.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Market Performance
 - 15.24.4 ImmunoCellular Therapeutics Business Overview
 - 15.24.5 ImmunoCellular Therapeutics Recent Developments
- 15.25 Incyte
 - 15.25.1 Incyte Basic Information
 - 15.25.2 Incyte Immuno-oncology Drugs Product Overview
 - 15.25.3 Incyte Immuno-oncology Drugs Product Market Performance
 - 15.25.4 Incyte Business Overview
 - 15.25.5 Incyte Recent Developments
- 15.26 Dendreon Corporation
 - 15.26.1 Dendreon Corporation Basic Information
 - 15.26.2 Dendreon Corporation Immuno-oncology Drugs Product Overview
 - 15.26.3 Dendreon Corporation Immuno-oncology Drugs Product Market Performance
 - 15.26.4 Dendreon Corporation Business Overview
 - 15.26.5 Dendreon Corporation Recent Developments
- 15.27 Agilent Technologies Inc.
 - 15.27.1 Agilent Technologies Inc. Basic Information
 - 15.27.2 Agilent Technologies Inc. Immuno-oncology Drugs Product Overview
 - 15.27.3 Agilent Technologies Inc. Immuno-oncology Drugs Product Market Performance
 - 15.27.4 Agilent Technologies Inc. Business Overview
 - 15.27.5 Agilent Technologies Inc. Recent Developments
- 15.28 Agenus Inc.
 - 15.28.1 Agenus Inc. Basic Information
 - 15.28.2 Agenus Inc. Immuno-oncology Drugs Product Overview

15.28.3	Agenus Inc. Immuno-oncology Drugs Product Market Performance
15.28.4	Agenus Inc. Business Overview
15.28.5	Agenus Inc. Recent Developments
15.29	Enzo Biochem
15.29.1	Enzo Biochem Basic Information
15.29.2	Enzo Biochem Immuno-oncology Drugs Product Overview
15.29.3	Enzo Biochem Immuno-oncology Drugs Product Market Performance
15.29.4	Enzo Biochem Business Overview
15.29.5	Enzo Biochem Recent Developments
15.30	Inc.
15.30.1	Inc. Basic Information
15.30.2	Inc. Immuno-oncology Drugs Product Overview
15.30.3	Inc. Immuno-oncology Drugs Product Market Performance
15.30.4	Inc. Business Overview
15.30.5	Inc. Recent Developments
16	Conclusion and Key FindingsList of Tables
Table 1.	Introduction of the Type
Table 2.	Introduction of the Application
Table 3.	Global Immuno-oncology Drugs Market Size by Type (M USD)
Table 4.	Global Immuno-oncology Drugs Market Size by Application (M USD)
Table 5.	Immuno-oncology Drugs Market Size Comparison by Region (M USD)
Table 6.	Global Immuno-oncology Drugs Sales (K MT) by Manufacturers (2020-2025)
Table 7.	Global Immuno-oncology Drugs Sales Market Share by Manufacturers (2020-2025)
Table 8.	Global Immuno-oncology Drugs Revenue (M USD) by Manufacturers (2020-2025)
Table 9.	Global Immuno-oncology Drugs Revenue Share by Manufacturers (2020-2025)
Table 10.	Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Drugs as of 2024)
Table 11.	Global Market Immuno-oncology Drugs Average Price (USD/MT) of Key Manufacturers (2020-2025)
Table 12.	Manufacturers Immuno-oncology Drugs Manufacturing Sites and Area Served
Table 13.	Manufacturers Immuno-oncology Drugs Product Type
Table 14.	Global Immuno-oncology Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 15.	Mergers & Acquisitions, Expansion Plans
Table 16.	Market Overview of Key Raw Materials
Table 17.	Midstream Market Analysis
Table 18.	Downstream Customer Analysis

Table 19. Key Development Trends

Table 20. Driving Factors

Table 21. Immuno-oncology Drugs Market Challenges

Table 22. Goldman Sachs' forecast real GDP growth rate for 2024-2026

Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027

Table 24. World Bank ' Forecast Real GDP Growth Rate For 2024-2026

Table 25. Immuno-oncology Drugs Market Size Comparison by Region (M USD)

Table 26. Global Immuno-oncology Drugs Market Size by Region (2020-2033) & (M USD)

Table 27. Global Immuno-oncology Drugs Market Size Market Share by Region (2020-2033)

Table 28. Global Immuno-oncology Drugs Sales by Region (2020-2033) & (K MT)

Table 29. Global Immuno-oncology Drugs Sales Market Share by Region (2020-2033)

Table 30. North America Immuno-oncology Drugs Market Size by Country (2020-2033) & (M USD)

Table 31. North America Immuno-oncology Drugs Sales by Country (2020-2033) & (K MT)

Table 32. North America Immuno-oncology Drugs Sales by Type (K MT)

Table 33. North America Immuno-oncology Drugs Market Size by Type (M USD)

Table 34. North America Immuno-oncology Drugs Sales (K MT) by Type (2020-2033)

Table 35. North America Immuno-oncology Drugs Market Size (M USD) by Type (2020-2033)

Table 36. North America Immuno-oncology Drugs Sales by Application (K MT)

Table 37. North America Immuno-oncology Drugs Market Size by Application (M USD)

Table 38. North America Immuno-oncology Drugs Sales (K MT) by Application (2020-2033)

Table 39. North America Immuno-oncology Drugs Market Size (M USD) by Application (2020-2033)

Table 40. Europe Immuno-oncology Drugs Market Size by Country (2020-2033) & (M USD)

Table 41. Europe Immuno-oncology Drugs Sales by Country (2020-2033) & (K MT)

Table 42. Europe Immuno-oncology Drugs Sales by Type (K MT)

Table 43. Europe Immuno-oncology Drugs Market Size by Type (M USD)

Table 44. Europe Immuno-oncology Drugs Sales (K MT) by Type (2020-2033)

Table 45. Europe Immuno-oncology Drugs Market Size (M USD) by Type (2020-2033)

Table 46. Europe Immuno-oncology Drugs Sales by Application (K MT)

Table 47. Europe Immuno-oncology Drugs Market Size by Application (M USD)

Table 48. Europe Immuno-oncology Drugs Sales (K MT) by Application (2020-2033)

Table 49. Europe Immuno-oncology Drugs Market Size (M USD) by Application

(2020-2033)

Table 50. Asia-Pacific Immuno-oncology Drugs Market Size by Country (2020-2025) & (M USD)

Table 51. Asia-Pacific Immuno-oncology Drugs Sales by Country (2020-2025) & (K MT)

Table 52. Asia-Pacific Immuno-oncology Drugs Sales by Type (K MT)

Table 53. Asia-Pacific Immuno-oncology Drugs Market Size by Type (M USD)

Table 54. Asia-Pacific Immuno-oncology Drugs Sales (K MT) by Type (2020-2033)

Table 55. Asia-Pacific Immuno-oncology Drugs Market Size (M USD) by Type (2020-2025)

Table 56. Asia-Pacific Immuno-oncology Drugs Sales by Application (K MT)

Table 57. Asia-Pacific Immuno-oncology Drugs Market Size by Application (M USD)

Table 58. Asia-Pacific Immuno-oncology Drugs Sales (K MT) by Application (2020-2033)

Table 59. Asia-Pacific Immuno-oncology Drugs Market Size (M USD) by Application (2020-2025)

Table 60. South America Immuno-oncology Drugs Market Size by Country (2020-2033) & (M USD)

Table 61. South America Immuno-oncology Drugs Sales by Country (2020-2033) & (K MT)

Table 62. South America Immuno-oncology Drugs Sales by Type (K MT)

Table 63. South America Immuno-oncology Drugs Market Size by Type (M USD)

Table 64. South America Immuno-oncology Drugs Sales (K MT) by Type (2020-2033)

Table 65. South America Immuno-oncology Drugs Market Size (M USD) by Type (2020-2033)

Table 66. South America Immuno-oncology Drugs Sales by Application (K MT)

Table 67. South America Immuno-oncology Drugs Market Size by Application (M USD)

Table 68. South America Immuno-oncology Drugs Sales (K MT) by Application (2020-2033)

Table 69. South America Immuno-oncology Drugs Market Size (M USD) by Application (2020-2033)

Table 70. Middle East and Africa Immuno-oncology Drugs Market Size by Country (2020-2033) & (M USD)

Table 71. Middle East and Africa Immuno-oncology Drugs Sales by Country (2020-2033) & (K MT)

Table 72. Middle East and Africa Immuno-oncology Drugs Sales by Type (K MT)

Table 73. Middle East and Africa Immuno-oncology Drugs Market Size by Type (M USD)

Table 74. Middle East and Africa Immuno-oncology Drugs Sales (K MT) by Type (2020-2033)

Table 75. Middle East and Africa Immuno-oncology Drugs Market Size (M USD) by Type (2020-2033)

Table 76. Middle East and Africa Immuno-oncology Drugs Sales by Application (K MT)

Table 77. Middle East and Africa Immuno-oncology Drugs Market Size by Application (M USD)

Table 78. Middle East and Africa Immuno-oncology Drugs Sales (K MT) by Application (2020-2033)

Table 79. Middle East and Africa Immuno-oncology Drugs Market Size (M USD) by Application (2020-2033)

Table 80. Global Immuno-oncology Drugs Production (K MT) by Region(2020-2025)

Table 81. Global Immuno-oncology Drugs Revenue (US\$ Million) by Region (2020-2025)

Table 82. Global Immuno-oncology Drugs Revenue Market Share by Region (2020-2025)

Table 83. Global Immuno-oncology Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 84. North America Immuno-oncology Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 85. Europe Immuno-oncology Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 86. Japan Immuno-oncology Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 87. China Immuno-oncology Drugs Production (K MT), Revenue (US\$ Million), Price (USD/MT) and Gross Margin (2020-2025)

Table 88. Global Immuno-oncology Drugs Sales by Type (K MT)

Table 89. Global Immuno-oncology Drugs Market Size by Type (M USD)

Table 90. Global Immuno-oncology Drugs Sales (K MT) by Type (2020-2033)

Table 91. Global Immuno-oncology Drugs Sales Market Share by Type (2020-2033)

Table 92. Global Immuno-oncology Drugs Market Size (M USD) by Type (2020-2033)

Table 93. Global Immuno-oncology Drugs Market Size Share by Type (2020-2033)

Table 94. Global Immuno-oncology Drugs Sales (K MT) by Application

Table 95. Global Immuno-oncology Drugs Market Size by Application(M USD)

Table 96. Global Immuno-oncology Drugs Sales by Application (2020-2033) & (K MT)

Table 97. Global Immuno-oncology Drugs Sales Market Share by Application (2020-2033)

Table 98. Global Immuno-oncology Drugs Market Size by Application (2020-2033) & (M USD)

Table 99. Global Immuno-oncology Drugs Market Share by Application (2020-2033)

Table 100. Global Immuno-oncology Drugs Sales Growth Rate by Application

(2020-2033)

Table 101. Amgen Basic Information

Table 102. Amgen Immuno-oncology Drugs Product Overview

Table 103. Amgen Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 104. Amgen Business Overview

Table 105. Amgen SWOT Analysis

Table 106. Amgen Recent Developments

Table 107. Inc Basic Information

Table 108. Inc Immuno-oncology Drugs Product Overview

Table 109. Inc Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 110. Inc Business Overview

Table 111. Inc SWOT Analysis

Table 112. Inc Recent Developments

Table 113. AstraZeneca Basic Information

Table 114. AstraZeneca Immuno-oncology Drugs Product Overview

Table 115. AstraZeneca Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 116. AstraZeneca Business Overview

Table 117. AstraZeneca SWOT Analysis

Table 118. AstraZeneca Recent Developments

Table 119. Plc Basic Information

Table 120. Plc Immuno-oncology Drugs Product Overview

Table 121. Plc Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 122. Plc Business Overview

Table 123. Plc Recent Developments

Table 124. Bristol-Myers Squibb Basic Information

Table 125. Bristol-Myers Squibb Immuno-oncology Drugs Product Overview

Table 126. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 127. Bristol-Myers Squibb Business Overview

Table 128. Bristol-Myers Squibb Recent Developments

Table 129. Celgene Corporation Basic Information

Table 130. Celgene Corporation Immuno-oncology Drugs Product Overview

Table 131. Celgene Corporation Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 132. Celgene Corporation Business Overview

Table 133. Celgene Corporation Recent Developments
Table 134. Eli Lilly and Company Basic Information
Table 135. Eli Lilly and Company Immuno-oncology Drugs Product Overview
Table 136. Eli Lilly and Company Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 137. Eli Lilly and Company Business Overview
Table 138. Eli Lilly and Company Recent Developments
Table 139. Merck and Co. Basic Information
Table 140. Merck and Co. Immuno-oncology Drugs Product Overview
Table 141. Merck and Co. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 142. Merck and Co. Business Overview
Table 143. Merck and Co. Recent Developments
Table 144. Hoffmann-La Roche AG Basic Information
Table 145. Hoffmann-La Roche AG Immuno-oncology Drugs Product Overview
Table 146. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 147. Hoffmann-La Roche AG Business Overview
Table 148. Hoffmann-La Roche AG Recent Developments
Table 149. Johnson and Johnson Basic Information
Table 150. Johnson and Johnson Immuno-oncology Drugs Product Overview
Table 151. Johnson and Johnson Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 152. Johnson and Johnson Business Overview
Table 153. Johnson and Johnson Recent Developments
Table 154. Novartis International AG Basic Information
Table 155. Novartis International AG Immuno-oncology Drugs Product Overview
Table 156. Novartis International AG Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 157. Novartis International AG Business Overview
Table 158. Novartis International AG Recent Developments
Table 159. AbbVie Basic Information
Table 160. AbbVie Immuno-oncology Drugs Product Overview
Table 161. AbbVie Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 162. AbbVie Business Overview
Table 163. AbbVie Recent Developments
Table 164. Inc. Basic Information
Table 165. Inc. Immuno-oncology Drugs Product Overview

Table 166. Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 167. Inc. Business Overview

Table 168. Inc. Recent Developments

Table 169. Pfizer Inc. Basic Information

Table 170. Pfizer Inc. Immuno-oncology Drugs Product Overview

Table 171. Pfizer Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 172. Pfizer Inc. Business Overview

Table 173. Pfizer Inc. Recent Developments

Table 174. Sanofi S.A. Basic Information

Table 175. Sanofi S.A. Immuno-oncology Drugs Product Overview

Table 176. Sanofi S.A. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 177. Sanofi S.A. Business Overview

Table 178. Sanofi S.A. Recent Developments

Table 179. EMD Serono Basic Information

Table 180. EMD Serono Immuno-oncology Drugs Product Overview

Table 181. EMD Serono Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 182. EMD Serono Business Overview

Table 183. EMD Serono Recent Developments

Table 184. Inc. Basic Information

Table 185. Inc. Immuno-oncology Drugs Product Overview

Table 186. Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 187. Inc. Business Overview

Table 188. Inc. Recent Developments

Table 189. Gilead Sciences Inc. Basic Information

Table 190. Gilead Sciences Inc. Immuno-oncology Drugs Product Overview

Table 191. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 192. Gilead Sciences Inc. Business Overview

Table 193. Gilead Sciences Inc. Recent Developments

Table 194. Prometheus Therapeutics and Diagnostics Basic Information

Table 195. Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Product Overview

Table 196. Prometheus Therapeutics and Diagnostics Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)

Table 197. Prometheus Therapeutics and Diagnostics Business Overview
Table 198. Prometheus Therapeutics and Diagnostics Recent Developments
Table 199. Aduro BioTech Basic Information
Table 200. Aduro BioTech Immuno-oncology Drugs Product Overview
Table 201. Aduro BioTech Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 202. Aduro BioTech Business Overview
Table 203. Aduro BioTech Recent Developments
Table 204. Galena Biopharma Basic Information
Table 205. Galena Biopharma Immuno-oncology Drugs Product Overview
Table 206. Galena Biopharma Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 207. Galena Biopharma Business Overview
Table 208. Galena Biopharma Recent Developments
Table 209. Bavarian Nordic Basic Information
Table 210. Bavarian Nordic Immuno-oncology Drugs Product Overview
Table 211. Bavarian Nordic Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 212. Bavarian Nordic Business Overview
Table 213. Bavarian Nordic Recent Developments
Table 214. Celldex Therapeutics Basic Information
Table 215. Celldex Therapeutics Immuno-oncology Drugs Product Overview
Table 216. Celldex Therapeutics Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 217. Celldex Therapeutics Business Overview
Table 218. Celldex Therapeutics Recent Developments
Table 219. ImmunoCellular Therapeutics Basic Information
Table 220. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Overview
Table 221. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 222. ImmunoCellular Therapeutics Business Overview
Table 223. ImmunoCellular Therapeutics Recent Developments
Table 224. Incyte Basic Information
Table 225. Incyte Immuno-oncology Drugs Product Overview
Table 226. Incyte Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 227. Incyte Business Overview
Table 228. Incyte Recent Developments
Table 229. Dendreon Corporation Basic Information

Table 230. Dendreon Corporation Immuno-oncology Drugs Product Overview
Table 231. Dendreon Corporation Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 232. Dendreon Corporation Business Overview
Table 233. Dendreon Corporation Recent Developments
Table 234. Agilent Technologies Inc. Basic Information
Table 235. Agilent Technologies Inc. Immuno-oncology Drugs Product Overview
Table 236. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 237. Agilent Technologies Inc. Business Overview
Table 238. Agilent Technologies Inc. Recent Developments
Table 239. Agenus Inc. Basic Information
Table 240. Agenus Inc. Immuno-oncology Drugs Product Overview
Table 241. Agenus Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 242. Agenus Inc. Business Overview
Table 243. Agenus Inc. Recent Developments
Table 244. Enzo Biochem Basic Information
Table 245. Enzo Biochem Immuno-oncology Drugs Product Overview
Table 246. Enzo Biochem Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 247. Enzo Biochem Business Overview
Table 248. Enzo Biochem Recent Developments
Table 249. Inc. Basic Information
Table 250. Inc. Immuno-oncology Drugs Product Overview
Table 251. Inc. Immuno-oncology Drugs Sales (K MT), Revenue (M USD), Price (USD/MT) and Gross Margin (2020-2025)
Table 252. Inc. Business Overview
Table 253. Inc. Recent Developments
List of Figures
Figure 1. Product Picture of Immuno-oncology Drugs
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Immuno-oncology Drugs Market Size (M USD), 2024-2033
Figure 5. Global Immuno-oncology Drugs Market Size (M USD) (2020-2033)
Figure 6. Global Immuno-oncology Drugs Sales (K MT) & (2020-2033)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 9. Evaluation Matrix of Regional Market Development Potential

- Figure 10. Immuno-oncology Drugs Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Immuno-oncology Drugs Product Life Cycle
- Figure 13. Immuno-oncology Drugs Sales Share by Manufacturers in 2024
- Figure 14. Global Immuno-oncology Drugs Revenue Share by Manufacturers in 2024
- Figure 15. Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
- Figure 16. Global Market Immuno-oncology Drugs Average Price (USD/MT) of Key Manufacturers in 2024
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Immuno-oncology Drugs Revenue in 2024
- Figure 18. Industry Chain Map of Immuno-oncology Drugs
- Figure 19. Global Immuno-oncology Drugs Market PEST Analysis
- Figure 20. Global Immuno-oncology Drugs Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Regional Market Development Potential
- Figure 26. Global Immuno-oncology Drugs Market Size by Region
- Figure 27. Global Immuno-oncology Drugs Market Size Market Share by Region (2020-2033)
- Figure 28. Global Immuno-oncology Drugs Sales Market Share by Region (2020-2033)
- Figure 29. North American Market Snapshot
- Figure 30. North America Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)
- Figure 31. North America Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)
- Figure 32. North America Immuno-oncology Drugs Market Size (M USD) by Country
- Figure 33. USA Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)
- Figure 34. USA Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)
- Figure 35. Canada Immuno-oncology Drugs Sales (K MT) and Growth Rate (2020-2033)
- Figure 36. Canada Immuno-oncology Drugs Market Size (M USD) and Growth Rate (2020-2033)
- Figure 37. Mexico Immuno-oncology Drugs Sales (Units) and Growth Rate (2020-2033)
- Figure 38. Mexico Immuno-oncology Drugs Market Size (M USD) and Growth Rate (2020-2033)

Figure 39. North America Immuno-oncology Drugs Market Size (M USD)by Type

Figure 40. North America Immuno-oncology Drugs Market Size (M USD) by Application

Figure 41. Europe Market Snapshot

Figure 42. Europe Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 43. Europe Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 44. Europe Immuno-oncology Drugs Market Size (M USD) by Country

Figure 45. Germany Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 46. Germany Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 47. France Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 48. France Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 49. U.K. Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 50. U.K. Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 51. Italy Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 52. Italy Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 53. Spain Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 54. Spain Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 55. Europe Immuno-oncology Drugs Market Size (M USD) by Type

Figure 56. Europe Immuno-oncology Drugs Market Size (M USD) by Application

Figure 57. Asia-Pacific Market Snapshot

Figure 58. Asia-Pacific Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 59. Asia-Pacific Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 60. Asia-Pacific Immuno-oncology Drugs Market Size (M USD) by Country

Figure 61. China Immuno-oncology Drugs Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. China Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Japan Immuno-oncology Drugs Sales and Growth Rate (2020-2025) & (K

MT)

Figure 64. Japan Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. South Korea Immuno-oncology Drugs Sales and Growth Rate (2020-2025) & (K MT)

Figure 66. South Korea Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 67. India Immuno-oncology Drugs Sales and Growth Rate (2020-2025) & (K MT)

Figure 68. India Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 69. Southeast Asia Immuno-oncology Drugs Sales and Growth Rate (2020-2025) & (K MT)

Figure 70. Southeast Asia Immuno-oncology Drugs Market Size and Growth Rate (2020-2025) & (M USD)

Figure 71. Asia-Pacific Immuno-oncology Drugs Market Size (M USD) by Type

Figure 72. Asia-Pacific Immuno-oncology Drugs Market Size (M USD) by Application

Figure 73. South America Market Snapshot

Figure 74. South America Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 75. South America Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 76. South America Immuno-oncology Drugs Market Size (M USD) by Country

Figure 77. Brazil Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 78. Brazil Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 79. Argentina Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 80. Argentina Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 81. Columbia Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 82. Columbia Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 83. South America Immuno-oncology Drugs Market Size (M USD) by Type

Figure 84. South America Immuno-oncology Drugs Market Size (M USD) by Application

Figure 85. Middle East and Africa Market Snapshot

Figure 86. Middle East and Africa Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 87. Middle East and Africa Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 88. Middle East and Africa Immuno-oncology Drugs Market Size (M USD) by Country

Figure 89. Saudi Arabia Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 90. Saudi Arabia Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 91. UAE Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 92. UAE Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 93. Egypt Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 94. Egypt Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 95. Nigeria Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 96. Nigeria Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 97. South Africa Immuno-oncology Drugs Sales and Growth Rate (2020-2033) & (K MT)

Figure 98. South Africa Immuno-oncology Drugs Market Size and Growth Rate (2020-2033) & (M USD)

Figure 99. Middle East and Africa Immuno-oncology Drugs Market Size (M USD) by Type

Figure 100. Middle East and Africa Immuno-oncology Drugs Market Size (M USD) by Application

Figure 101. Global Immuno-oncology Drugs Production Market Share by Region (2020-2025)

Figure 102. North America Immuno-oncology Drugs Production (K MT) Growth Rate (2020-2025)

Figure 103. Europe Immuno-oncology Drugs Production (K MT) Growth Rate (2020-2025)

Figure 104. Japan Immuno-oncology Drugs Production (K MT) Growth Rate (2020-2025)

Figure 105. China Immuno-oncology Drugs Production (K MT) Growth Rate (2020-2025)

Figure 106. Evaluation Matrix of Segment Market Development Potential (Type)

Figure 107. Global Immuno-oncology Drugs Market Size by Type (M USD)

Figure 108. Sales Market Share of Immuno-oncology Drugs by Type (2020-2033)

Figure 109. Sales Market Share of Immuno-oncology Drugs by Type in 2024

Figure 110. Market Size Share of Immuno-oncology Drugs by Type (2020-2033)

Figure 111. Market Size Share of Immuno-oncology Drugs by Type in 2024

Figure 112. Global Immuno-oncology Drugs Price (USD/MT) by Type (2020-2033)

Figure 113. Evaluation Matrix of Segment Market Development Potential (Application)

Figure 114. Global Immuno-oncology Drugs Market Size by Application(M USD)

Figure 115. Global Immuno-oncology Drugs Market Share by Application

Figure 116. Global Immuno-oncology Drugs Sales Market Share by Application
(2020-2033)

Figure 117. Global Immuno-oncology Drugs Sales Market Share by Application in 2024

Figure 118. Global Immuno-oncology Drugs Market Share by Application (2020-2033)

Figure 119. Global Immuno-oncology Drugs Market Share by Application in 2024

Figure 120. Global Immuno-oncology Drugs Sales Growth Rate by Application
(2020-2033)

I would like to order

Product name: Global Immuno-oncology Drugs Market Research Report 2025(Status and Outlook)

Product link: <https://marketpublishers.com/r/G1A6CE4CF3D0EN.html>

Price: US\$ 3,680.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G1A6CE4CF3D0EN.html>